Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Barrett Esophagus
- Sponsor
- Pentax Medical
- Enrollment
- 150
- Locations
- 11
- Primary Endpoint
- Percentage of patients with baseline LGD who have complete eradication of all dysplasia
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the treatment of previously-untreated ("treatment naïve") Barrett's Esophagus (BE)
Detailed Description
Coldplay III is a multi-center, prospective study that will provide evidence of the efficacy and safety of the System in treatment of patients with previously untreated (treatment naïve) low grade dysplasia (LGD) or high grade dysplasia (HGD) BE. Subjects may have a maximum of five (5) ablation treatment sessions during their 12 months of study participation to achieve complete eradication of their dysplastic BE and intestinal metaplasia. As many ablations as needed to treat the dysplastic areas are allowed in each treatment session at the discretion of the investigator.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Low- or high-grade non-nodular, previously untreated ("treatment naïve") dysplastic BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer (ImCA) is identified during patient screening, this may be treated with Endoscopic Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion.
- •BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1
- •Older than 18 years of age at time of consent
- •Operable per institution's standards
- •Provides written informed consent on the approved informed consent form
- •Willing and able to comply with study requirements for follow-up
Exclusion Criteria
- •Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological analysis
- •Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope (patients may have the stenosis/stricture dilated and then be treated with CryoBalloon ablation under this protocol at a subsequent procedure ≥2 weeks later)
- •Symptomatic untreated strictures
- •Any endoscopically-visualized abnormalities such as ulcers, masses or nodules. Neoplastic nodules must first be treated with EMR ≥6 weeks prior to planned treatment under this protocol.
- •History of esophageal cancer more extensive than T1a or not meeting criteria for low risk of recurrence (confirmed by EMR pathology results negative for positive margin, poorly differentiated carcinoma, and lymphovascular invasion)
- •History of esophageal varices
- •Large (\>4cm) hiatal hernia
- •Prior distal esophagectomy
- •Any clinical or histological suspicion of esophageal adenocarcinoma invading into the submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with positive deep margin by EMR
- •Active esophagitis grade B or higher
Outcomes
Primary Outcomes
Percentage of patients with baseline LGD who have complete eradication of all dysplasia
Time Frame: 12 months
Incidence of serious, CryoBalloon Ablation System-related adverse events
Time Frame: 12 months
percentage of patients with baseline HGD who have complete eradication of all dysplasia
Time Frame: 12 months
percentage of all treated patients who have complete eradication of all dysplasia (CE-D)
Time Frame: 12 months
Secondary Outcomes
- Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer(12 months)
- Incidence of post procedure chest discomfort events / Pain score >0 and <5(Day 1)
- Mean and Median Pain score on Day 1 post procedure(Day 1)
- Incidence of all treatment-related and all serious, non-treatment-related adverse events(12 months)
- Mean and Median Pain score on Day 7 post procedure(Day 7)
- Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM(12 months)
- Percentage of subjects with complete eradication of all esophageal intestinal metaplasia (CE-IM)(12 months)
- Incidence of post procedure chest discomfort events / Pain score ≥5 and requiring narcotic analgesic(Day 7)
- Rate of (CE-D) and all esophageal (CE-IM) will be reported as a percentage of all subjects enrolled, and stratified by baseline dysplasia grade(24 and 36 months)